Recurrent Primary Peritoneal Carcinoma Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0031168 (Recurrent Primary Peritoneal Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02901899Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerTreatment
NCT02853318Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment